Welcome to our dedicated page for Seres Therapeutics SEC filings (Ticker: MCRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Seres Therapeutics, Inc. (MCRB) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents include Form 8-K current reports, which Seres uses to announce quarterly financial results, operational updates, leadership changes, cost-reduction actions, and other material events.
For a clinical-stage live biotherapeutics company like Seres, SEC filings are a primary source of information on the status of its programs and financial position. In recent 8-K filings, the company has reported results and updates related to its lead investigational candidate SER-155, including descriptions of Phase 1b data in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT), regulatory designations such as Breakthrough Therapy and Fast Track, and ongoing interactions with the U.S. Food and Drug Administration regarding a planned Phase 2 study design.
Filings also discuss the company’s classification of historical VOWST™ operating results as discontinued operations following the sale of that asset to Nestlé Health Science, as well as the provision of manufacturing services under a Transition Services Agreement. Additional disclosures cover cash runway expectations, workforce reductions, and business development efforts aimed at securing capital or strategic partnerships to advance SER-155 and other live biotherapeutic candidates.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand topics such as trial plans, risk factor discussions, and material corporate actions. Users can review 8-Ks and other filings in real time as they are posted to EDGAR, and use AI-generated insights to interpret how Seres’ regulatory and financial disclosures relate to its live biotherapeutics pipeline and overall strategy.
Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics (MCRB), reported equity changes on a Form 4. Restricted stock units vested and settled on 08/15/2025: 141 RSUs and 97 RSUs were reported as acquired/settled, each representing one share. A subsequent sale on 08/18/2025 disposed of 73 shares at $16.65 per share under a Rule 10b5-1 plan adopted April 13, 2023 to cover taxes related to vesting. Following these transactions the filing shows 4,548 shares beneficially owned and remaining RSU balances of 844 and 976 as reported.
Teresa L. Young, EVP, Chief Commercial & Strategy Officer of Seres Therapeutics, Inc. (Ticker: MCRB), reported vesting and settlement of restricted stock units and a small sale of common stock in August 2025. On 08/15/2025 two tranches of restricted stock units were reported (133 and 97 RSUs) that represent contingent rights to receive shares; the filings show post-transaction beneficial ownership figures of 5,177 and 5,274 shares respectively. On 08/18/2025 the reporting person sold 59 shares at $16.65, executed under a Rule 10b5-1 instruction adopted March 5, 2023, described as intended solely to cover taxes relating to RSU vesting. The Form 4 is signed by an attorney-in-fact on 08/19/2025.
FAQ
What is the current stock price of Seres Therapeutics (MCRB)?
What is the market cap of Seres Therapeutics (MCRB)?
